Nurix Therapeutics (NRIX) Cash & Equivalents (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Cash & Equivalents data on file, last reported at $67.7 million in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 19.67% year-over-year to $67.7 million in Q2 2026; TTM through May 2026 was $67.7 million, a 19.67% decrease from a year earlier, with the FY2025 full-year figure at $247.0 million, up 124.52% from the prior year.
• Cash & Equivalents for Q2 2026 stood at $67.7 million, down from $71.2 million in the prior quarter.
• Over the last five years, Cash & Equivalents for NRIX reached as high as $247.0 million in Q4 2025 and fell as low as $33.6 million in Q1 2023.
• Historically, Cash & Equivalents has averaged $79.0 million across 5 years, with a median of $69.4 million in 2026.
• Across the five-year window, Cash & Equivalents sank 77.93% in 2022 and jumped 134.12% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $64.5 million in 2022, then fell by 15.27% to $54.6 million in 2023, then soared by 101.36% to $110.0 million in 2024, then jumped by 124.52% to $247.0 million in 2025, then slumped by 72.59% to $67.7 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $67.7 million in Q2 2026, $71.2 million in Q1 2026, and $247.0 million in Q4 2025.